Literature DB >> 14527163

Chondromodulin-I expression in rat articular cartilage.

Hiroshi Kitahara1, Tadashi Hayami, Kunihiko Tokunaga, Naoto Endo, Haruko Funaki, Yutaka Yoshida, Eishin Yaoita, Tadashi Yamamoto.   

Abstract

The localization and expression of chondromodulin-I (ChM-I), an angiogenesis inhibitor, in the rat articular cartilage during maturation from 2 to 10 weeks of age were examined by immunohistochemistry, Western blot analysis and ribonuclease protection assay, and the results were compared with those in the epiphyseal cartilage. ChM-I was found to be diffusely immunostained in the inter-territorial space of the cartilage matrix from the intermediate to the deep layers at the immature stage. As the articular cartilage matured, the immunoreactivity was localized around the hypertrophic chondrocytes in the deep layer and the immunoreactivity became weak after maturation. In contrast, the ChM-I immunoreactivity was intense in the epiphyseal cartilage at all ages examined. ChM-I was detected by Western blotting as a broad band or occasionally as a cluster of multiple bands (approximately 25 kDa) in both the articular and the epiphyseal cartilage. The intensity of the bands decreased gradually with age in the articular cartilage, but was unchanged in the epiphyseal cartilage at all ages. Ribonuclease protection assay revealed that ChM-I mRNA also decreased gradually with age in the articular cartilage in parallel with the maturation of the articular cartilage, while no decrease in ChM-I mRNA was found in the epiphyseal cartilage. The expression of ChM-I mRNA in the articular cartilage was less than that in the epiphyseal cartilage at all ages. The decrease in amount of ChM-I in the mature articular cartilage suggests that ChM-I plays a more important role in the maintenance of avascularity in the immature articular cartilage than in the mature one. The avascular condition may be preserved by angiogenic inhibitors or mechanisms other than ChM-I in the mature articular cartilage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527163     DOI: 10.1679/aohc.66.221

Source DB:  PubMed          Journal:  Arch Histol Cytol        ISSN: 0914-9465


  8 in total

1.  Time-sequential modulation in expression of growth factors from platelet-rich plasma (PRP) on the chondrocyte cultures.

Authors:  Se-Il Park; Hye-Rim Lee; Sukyoung Kim; Myun-Whan Ahn; Sun Hee Do
Journal:  Mol Cell Biochem       Date:  2011-09-29       Impact factor: 3.396

2.  Thrombospondin-1 inhibits ossification of tissue engineered cartilage constructed by ADSCs.

Authors:  Aiguo Xie; Jixin Xue; Gan Shen; Lanjun Nie
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

3.  Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis.

Authors:  Toshihiro Nagai; Masato Sato; Miyuki Kobayashi; Munetaka Yokoyama; Yoshiki Tani; Joji Mochida
Journal:  Arthritis Res Ther       Date:  2014-09-18       Impact factor: 5.156

4.  Intravenous administration of anti-vascular endothelial growth factor humanized monoclonal antibody bevacizumab improves articular cartilage repair.

Authors:  Toshihiro Nagai; Masato Sato; Toshiharu Kutsuna; Mami Kokubo; Goro Ebihara; Naoshi Ohta; Joji Mochida
Journal:  Arthritis Res Ther       Date:  2010-09-24       Impact factor: 5.156

5.  Developmental mechanisms in articular cartilage degradation in osteoarthritis.

Authors:  Elena V Tchetina
Journal:  Arthritis       Date:  2010-12-29

6.  Biomimetic strategies for fracture repair: Engineering the cell microenvironment for directed tissue formation.

Authors:  Wollis J Vas; Mittal Shah; Rawiya Al Hosni; Helen C Owen; Scott J Roberts
Journal:  J Tissue Eng       Date:  2017-04-24       Impact factor: 7.813

7.  Platelet-rich plasma induces post-natal maturation of immature articular cartilage and correlates with LOXL1 activation.

Authors:  Yadan Zhang; Ben J Morgan; Rachel Smith; Christopher R Fellows; Catherine Thornton; Martyn Snow; Lewis W Francis; Ilyas M Khan
Journal:  Sci Rep       Date:  2017-06-16       Impact factor: 4.379

8.  Scleraxis is a transcriptional activator that regulates the expression of Tenomodulin, a marker of mature tenocytes and ligamentocytes.

Authors:  Chisa Shukunami; Aki Takimoto; Yuriko Nishizaki; Yuki Yoshimoto; Seima Tanaka; Shigenori Miura; Hitomi Watanabe; Tetsushi Sakuma; Takashi Yamamoto; Gen Kondoh; Yuji Hiraki
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.